Literature DB >> 24166214

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

M Lemaire1, M D'Huyvetter2, T Lahoutte3, E Van Valckenborgh1, E Menu1, E De Bruyne1, P Kronenberger4, U Wernery5, S Muyldermans6, N Devoogdt7, K Vanderkerken1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24166214     DOI： 10.1038/leu.2013.292

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  The 5TMM series: a useful in vivo mouse model of human multiple myeloma.

Authors:  K Asosingh; J Radl; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Hematol J       Date:  2000

2.  Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.

Authors:  Matthias D'Huyvetter; An Aerts; Catarina Xavier; Ilse Vaneycken; Nick Devoogdt; Marlies Gijs; Nathalie Impens; Sarah Baatout; Bernard Ponsard; Serge Muyldermans; Vicky Caveliers; Tony Lahoutte
Journal:  Contrast Media Mol Imaging       Date:  2012 Mar-Apr       Impact factor: 3.161

Review 3.  Nanobodies as novel agents for cancer therapy.

Authors:  Hilde Revets; Patrick De Baetselier; Serge Muyldermans
Journal:  Expert Opin Biol Ther       Date:  2005-01       Impact factor: 4.388

4.  Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Authors:  Caroline Rousseau; Ludovic Ferrer; Stéphane Supiot; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Pierre Baumgartner; John Wijdenes; Marie Lacombe; Jacques Barbet; Thierry Guillaume; Philippe Moreau; Jean Luc Harousseau; Françoise Kraeber-Bodéré; Michel Cherel
Journal:  Tumour Biol       Date:  2012-03-03

5.  Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.

Authors:  D Ma; M R McDevitt; E Barendswaard; L Lai; M J Curcio; V Pellegrini; M W Brechbiel; D A Scheinberg
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

6.  SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.

Authors:  Stéphanie Put; Steve Schoonooghe; Nick Devoogdt; Evelien Schurgers; Anneleen Avau; Tania Mitera; Matthias D'Huyvetter; Patrick De Baetselier; Geert Raes; Tony Lahoutte; Patrick Matthys
Journal:  J Nucl Med       Date:  2013-02-27       Impact factor: 10.057

Review 7.  Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.

Authors:  Jens De Vos; Nick Devoogdt; Tony Lahoutte; Serge Muyldermans
Journal:  Expert Opin Biol Ther       Date:  2013-05-16       Impact factor: 4.388

Review 8.  Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer.

Authors:  Steve Schoonooghe; Damya Laoui; Jo A Van Ginderachter; Nick Devoogdt; Tony Lahoutte; Patrick De Baetselier; Geert Raes
Journal:  Immunobiology       Date:  2012-07-21       Impact factor: 3.144

Review 9.  Targeted therapy of multiple myeloma.

Authors:  Nathan G Dolloff; Giampaolo Talamo
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.

Authors:  Shiri Moshitzky; Tova Kukulansky; Joseph Haimovich; Nurit Hollander
Journal:  Immunol Cell Biol       Date:  2008-01-15       Impact factor: 5.126
View more
  23 in total

1.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

2.  131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.

Authors:  Matthias D'Huyvetter; Jens De Vos; Catarina Xavier; Marek Pruszynski; Yann G J Sterckx; Sam Massa; Geert Raes; Vicky Caveliers; Michael R Zalutsky; Tony Lahoutte; Nick Devoogdt
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.

Authors:  Zhengyuan Zhou; Satish K Chitneni; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioorg Med Chem       Date:  2018-03-15       Impact factor: 3.641

Review 4.  Radiotheranostic Agents in Hematological Malignancies.

Authors:  Jo Caers; Elodie Duray; Louise Vrancken; Guillaume Marcion; Valentina Bocuzzi; Kim De Veirman; Ahmet Krasniqi; Margaux Lejeune; Nadia Withofs; Nick Devoogdt; Mireille Dumoulin; Amelie Eriksson Karlström; Matthias D'Huyvetter
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.

Authors:  Zhengyuan Zhou; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioconjug Chem       Date:  2018-11-14       Impact factor: 4.774

6.  Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer.

Authors:  Thinzar M Lwin; Sophie Hernot; Hannah Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Pieterjan Debie; Robert M Hoffman; Michael Bouvet
Journal:  Surgery       Date:  2020-05-04       Impact factor: 3.982

Review 7.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

8.  Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

Authors:  Anchal Ghai; Dolonchampa Maji; Nicholas Cho; Chantiya Chanswangphuwana; Michael Rettig; Duanwen Shen; John DiPersio; Walter Akers; Farrokh Dehdashti; Samuel Achilefu; Ravi Vij; Monica Shokeen
Journal:  J Nucl Med       Date:  2017-10-12       Impact factor: 10.057

Review 9.  Nanobody: the "magic bullet" for molecular imaging?

Authors:  Rubel Chakravarty; Shreya Goel; Weibo Cai
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

Review 10.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.

Authors:  Matthias D'Huyvetter; Catarina Xavier; Vicky Caveliers; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Expert Opin Drug Deliv       Date:  2014-07-18       Impact factor: 6.648
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.